NCT00511121View on ClinicalTrials.gov

Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)

PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

April 30, 2001

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG

STI571 and PEG INTRON

Sponsors

Collaborators (2)

Schering-Plough

All Listed Sponsors

collaborator

Novartis

INDUSTRY

collaborator

Schering-Plough

INDUSTRY

lead

University of Bologna

OTHER